Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to detail his many portfolio moves. DOGE Stimulus Checks ...

Jefferies lowered the firm’s price target on Vertex (VERX) to $48 from $62 and keeps a Buy rating on the shares. The company’s results beat on ...

In a report released today, Patrick Walravens from JMP Securities maintained a Buy rating on Vertex (VERX – Research Report), with a price ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

KING OF PRUSSIA, Pa. — KING OF PRUSSIA, Pa. — Vertex, Inc. (VERX) on Thursday reported a loss of $67.8 million in its fourth quarter. On a per-share basis, the King Of Prussia, Pennsylvania-based ...

Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ETCompany ParticipantsJoe Crivelli – Vice President of ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Arc’teryx has introduced four new technical models to its footwear roster: Norvan LD 4, Vertex Speed, Norvan Nivalis, Konseal ...

Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today announced the ...

"If we do our jobs right, and you come back a year from now, this place is going to be a buzzing hive" -- Vertex Executive ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...

Vertex (VERX) delivered earnings and revenue surprises of 7.14% and 1.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?